Alexandre A. da Silva, Jussara M. do Carmo, and John E. Hall
INTRODUCTION
In the past 25-35 years, we have witnessed an unprecedented increase in the prevalence of obesity in developing as well as industrialized countries, where over 1 billion people are estimated to be obese or overweight [1] . In the USA, approximately 35 .7% of adults are obese with body mass index (BMI) greater than 30 and more than two-thirds of the population are overweight, accounting for more than US $150 billion per year in medical costs [2 && ]. Even more alarming is the increasing number of overweight and obese children and adolescents, which has tripled since 1980; recent estimates indicate that 18.4% of 4-year olds are obese, and even higher rates of obesity are observed in black and Native American children as well as in children of Hispanic origin [3] .
OBESITY SHIFTS THE DISTRIBUTION OF BLOOD PRESSURE TOWARD HIGHER VALUES
Being overweight or obese markedly increases the risk for cardiovascular disease via several mechanisms, including diabetes, dyslipidemia, atherosclerosis, renal disease, and hypertension [4, 5] . For instance, risk estimates from population studies suggest that excess weight gain may contribute to as much as 80-90% of the risk for diabetes and other metabolic disorders and up to 65-75% of the risk for essential hypertension [4] . Although the prevalence of hypertension is higher in obese than in lean populations, not all obese individuals, when assessed by standard clinical criteria, are found to be hypertensive. However, excess weight gain shifts the distribution of blood pressure (BP) toward higher values. Thus, obese individuals not classified as being hypertensive would have lower BP at a lower body weight [5, 6] . This concept is supported by the nearly linear relationship between BMI and BP, by the fact that excess weight gain predicts future development of hypertension [7] , and that weight loss helps prevent the development of hypertension and reduces BP in most hypertensive individuals [8] .
MECHANISMS OF INCREASED BLOOD PRESSURE IN OBESITY: IMPORTANT ROLE OF THE SYMPATHETIC NERVOUS SYSTEM
Despite the established importance of obesity as a major cause of essential hypertension, the mechanisms by which excess weight gain elevates BP are not fully understood. Obesity-related hypertension is associated with sodium retention and impaired renal-pressure natriuresis (rightward shift in the pressure-natriuresis curve toward hypertensive levels) [7, 9] . This appears to be mediated, at least in part, by the activation of the reninangiotensin-aldosterone system (RAAS), physical compression of the kidneys by surrounding visceral fat and increased renal sinus fat, and increased sympathetic nervous system (SNS) activity [7] . Although these three main factors are closely interrelated and act in concert to impair renal-pressure natriuresis and raise BP in obese individuals, in this review we will focus on the role of increased SNS activity.
OBESITY IS ASSOCIATED WITH TISSUE-SPECIFIC ACTIVATION OF THE SYMPATHETIC NERVOUS SYSTEM
Excess weight gain, especially when accompanied by increased visceral adiposity, is associated with increased SNS activity which has been shown to participate in the development of hypertension in obese humans as well as in animal models of dietinduced obesity [10, 11] . The rise in SNS activity in diet-induced obesity appears to develop as early as 1 week after exposure to high-fat diets [12 && ], and even modest weight gain in nonobese individuals is associated with increased SNS activity [10] . Chronic pharmacological blockade of adrenergic receptors also causes greater reductions in BP in obese compared with lean hypertensive individuals [13] . However, the rise in SNS activity in obesity is modest and occurs only in certain organs and tissues instead of generalized whole-body sympathetic activation. For example, in obese individuals, SNS activity in skeletal muscle and the kidneys is elevated, whereas cardiac sympathetic activity is minimally increased, or even reduced, because of baroreflex inhibition [14] . Moreover, increased renal SNS activity leading to sodium retention and impaired pressurenatriuresis is the primary mechanism for elevated BP with excess weight gain rather than peripheral vasoconstriction caused by massive widespread SNS activation [6] .
In addition to being tissue specific, increased SNS activity in obesity also appears to vary according to ethnicity and body fat distribution with visceral obesity eliciting greater SNS activation than subcutaneous obesity [6] . The reasons for this stronger association between visceral obesity and SNS activation when compared to abdominal or lower body obesity have not been widely studied, and in most human studies muscle SNS activity has been evaluated rather than renal SNS activity. Thus, additional studies are needed to examine the influence of body fat distribution and differential regulation of SNS activity, and its close association with increased BP in obesity.
Several factors have been proposed to contribute to increased SNS activity in obesity including impaired baroreflex sensitivity, angiotensin II, hyperinsulinemia, sleep apnea, hypoghrelinemia, and hypoadiponectemia. The role of these factors in obesity-induced SNS activation and hypertension has been previously reviewed [15] , and in this brief review we focus mainly on two other factors that appear to be key players in linking excess weight gain with increased SNS activity: hyperleptinemia and activation of the brain pro-opiomelanocortin (POMC) neurons and melanocortin-4 receptors (MC4R).
KEY POINTS
Excess weight gain is a major preventable cause of human essential hypertension.
Renal sympathetic overactivity contributes to sodium retention and elevated BP in obesity.
Hyperleptinemia and activation of the brain melanocortin system (MC4R) play a key role in linking obesity, sympathetic activation, and elevated BP in obesity.
LEPTIN REGULATES BODY WEIGHT HOMEOSTASIS AND INCREASES SYMPATHETIC NERVOUS SYSTEM ACTIVITY AND BLOOD PRESSURE
Leptin, a peptide hormone secreted by the adipocytes in proportion to body fat mass, crosses the blood-brain barrier via a saturable transport system to activate its receptors in various regions of the central nervous system (CNS), especially in the hypothalamus and brainstem, to reduce appetite and increase energy expenditure [16] . Leptin deficiency or leptin receptor mutations that prevent normal activation of its intracellular signaling events lead to morbid early-onset obesity in humans and experimental animals models [17] . Despite marked obesity and many other characteristics of what has been termed 'metabolic syndrome' including hyperinsulinemia, dyslipidemia, hyperglycemia, visceral adiposity, and insulin resistance, individuals with leptin gene mutations are not hypertensive and do not exhibit increased SNS activity as would be anticipated based on their increased adiposity; in fact, they exhibit postural hypotension and attenuated RAAS to upright posture [18] . Further evidence supporting a role for leptin in contributing to increased SNS activity and hypertension in obesity derives from studies showing that acute leptin injections, either peripherally or directly into the brain ventricles, raise renal SNS activity [19] . Moreover, chronic infusion of leptin in lean rodents to achieve plasma levels that mimic those observed in obesity causes gradual elevation in BP over several days that can be completely abolished by chronic a and b adrenergic receptor blockade [20] ; and similar to diet-induced obesity, the gradual rise in BP during chronic leptin infusion suggests slow-acting mechanisms, including modest renal SNS activation to promote sodium retention, rather than massive widespread SNS activation to promote peripheral vasoconstriction. Collectively, these observations suggest that hyperleptinemia may be an important link between obesity, SNS activation, and hypertension.
OBESITY MAY BE ASSOCIATED WITH 'SELECTIVE' LEPTIN RESISTANCE
Another intriguing aspect of leptin-induced elevation in BP in nonobese animals is that it occurs concomitantly with marked reductions in appetite and significant weight loss, which would normally be associated with decreased BP. Thus, in the absence of these metabolic actions of leptin to promote weight loss and reduce appetite, the effects of leptin on SNS activity and on BP may be exacerbated. In fact, it is believed this scenario occurs in obesity in which 'selective' resistance to the appetite and metabolic actions of leptin may develop, whereas leptin's cardiovascular effects remain unaltered or even enhanced (Fig. 1) . The fact that most obese individuals have high circulating leptin levels and continue to ingest excess calories corroborates the notion that obesity is associated with resistance to the anorexic effects of leptin; but the observation that intracerebroventricular leptin administration causes normal or even greater renal SNS activation in obese animals fed high-fat diet when compared to lean controls [21 && ], while its ability to acutely reduce food intake is impaired [19] , is consistent with the hypothesis that obesity causes selective resistance to the metabolic effects of leptin instead of complete resistance to its many physiological actions. The mechanisms by which excess weight gain leads to 'selective' leptin resistance, however, are still unclear.
Site-specific activation of leptin receptors and differential activation of intracellular signaling events may contribute to selective leptin resistance in obesity (Fig. 1) . Leptin receptors have a wide distribution throughout the brain and most previous studies aimed at identifying the specific sites responsible for the effects of leptin on appetite regulation, using genetic approaches, have almost invariably failed to recapitulate the obesity observed in animals with whole-brain deletion of leptin receptors. Vong et al. [22 & ], however, recently showed that deleting leptin receptors in GABAergic neurons recapitulates most of the obese phenotype observed in leptin deficiency including severe earlyonset obesity, hyperphagia, hyperglycemia, and hyperinsulinemia; but as GABAergic neurons are numerous and widely distributed it is still unclear which neuronal types or brain sites are most important in mediating the effects of leptin on appetite and body weight homeostasis. In addition, whether the obesity observed in mice with leptin receptors deleted in GABAergic neurons is accompanied by elevations in BP is unknown. The hypothalamus and the brainstem have received intense attention as potential sites mediating the actions of leptin on SNS activity and BP regulation. For instance, deletion of leptin receptors in the arcuate nucleus of the hypothalamus markedly reduced the acute effects of leptin to increase renal SNS activity and attenuated the rise in BP induced by high-fat feeding [23] . It has been hypothesized that each of the three main intracellular signaling pathways stimulated by leptin receptor activation may exert differential control of leptin's many physiological actions. Leptin receptor activation triggers Janus tyrosine kinase 2 (Jak 2), leading to the phosphorylation of specific tyrosine residues along the C-terminal domain of the leptin receptor that activates three distinct signaling events [11] : latent signal transducers and activators of transcription 3 (STAT3) which regulates transcription of leptin target genes; insulin receptor substrate 2 (IRS2) which activates phosphatidylinositol 3-kinase (PI3K); and Src homology protein 2 (SHP2) which activates mitogen-activated protein kinase (MAPK). Although CNS deletion of each of these signaling pathways results in varying degrees of obesity, neuron-specific deletion of the STAT3 pathway appears to be the only one capable of mimicking the obesity and hyperphagia found in leptin deficient animals [24] . Deletion of SHP2 or IRS2 pathways in the entire brain or in forebrain neurons causes only mild obesity and modest hyperphagia and may be more important in mediating other metabolic actions of leptin such as increased energy expenditure and improved glucose regulation [11] . However, the individual contribution of STAT3, IRS2, and SHP2 pathways to the effects of leptin on SNS activity and BP regulation have not been clearly defined and only acute pharmacological studies have been reported.
THE CENTRAL NERVOUS SYSTEM MELANOCORTIN SYSTEM MEDIATES LEPTIN EFFECTS ON SYMPATHETIC NERVOUS SYSTEM ACTIVITY AND BLOOD PRESSURE
Although the precise intracellular events and brain sites by which leptin regulates energy balance and BP are not fully understood, there is strong evidence that leptin requires activation of the brain melanocortin system to exert most of its effects on renal sympathetic nerve activity (RSNA) and BP. Mice with MC4R deficiency are hyperphagic and obese, and exhibit most characteristics of metabolic syndrome that are also observed in leptin deficiency such as visceral adiposity, hyperinsulinemia and insulin resistance, but these mice are not hypertensive despite marked hyperleptinemia [25] ; deletion of leptin receptors in POMC neurons, which are particularly abundant in the arcuate nucleus of the hypothalamus, also completely abolished the chronic effects of leptin to raise BP [26 & ]; and mutations in the POMC or MC4R genes also lead to severe early-onset obesity and pronounced dysregulation of appetite in humans [27] . However, it appears that other factors in addition to leptin contribute to body weight regulation by the activation of POMC neurons as genetic deletion of leptin receptor in POMC neurons causes only mild obesity and does not completely abrogate the chronic anorexic effects of leptin [26 & ], suggesting that POMC neurons may play a key role in leptin's ability to selectively regulate RSNA and BP independent of its anorexic effects. However, deletion of MC4R does markedly attenuate the effects of leptin to reduce appetite in mice [28] .
MC4R is not only important for food intake and body weight regulation, but also may be a key component linking obesity and hyperleptinemia with increased SNS activity and hypertension. Obese MC4R-deficient mice are normotensive when compared to lean wildtype controls and they are resistant to the pressor effects of chronic leptin administration [28] , and activation of MC4R using synthetic agonists increases RSNA activity and BP [11] . The importance of the brain melanocortin system, particularly the MC4R, in contributing to obesity-induced elevations in RSNA and BP is also supported by the studies in humans with MC4R mutations. These individuals have reduced 24-h norepinephrine excretion, reduced diastolic and systolic BPs, and lower prevalence of hypertension than obese individuals with normal MC4R function [29 && ]. Also, pharmacological activation of MC4R in humans markedly elevates BP, similar to the responses observed in rodents [11,29 && ]. Therefore, in humans as well as in rodents, chronic MC4R stimulation raises BP and the presence of a functional POMC-MC4R pathway appears to be necessary for obesity and hyperleptinemia to increase SNS activity and BP.
In addition to mediating the effects of leptin, activation of MC4R may exert a more fundamental role in modulating SNS activity in response to other stimuli. For example, pharmacological antagonism of MC4R markedly reduced BP in spontaneous hypertensive rats (SHRs) (an experimental model of hypertension with increased SNS activity) to the same extent achieved by adrenergic receptor blockade [30] . The effects of various other peptides that induce SNS activation and elevate BP are also prevented by MC4R antagonism [31, 32] . In addition, MC4R blockade caused greater BP reduction in obese compared with lean Zucker rats, demonstrating a role for MC4R in regulating SNS activity and BP even in models that lack normal leptin actions [33 & ].
FACTORS IN OBESITY THAT MAY EXACERBATE THE PRESSOR ACTIONS OF THE LEPTIN-MC4R AXIS
Despite clear evidence that leptin and MC4R are important for excess weight gain to increase RSNA and BP, the rise in BP observed during chronic administration of leptin or MC4R agonists is modest. One factor that may offset part of the hypertensive effects of leptin-MC4R activation is the weight loss that often occurs when leptin or MC4R agonists are administered. Another potential explanation for the modest hypertensive effects of leptin and MC4R agonists in lean animals is that obesity may be associated with other factors that enhance the chronic pressor actions of the leptin-MC4R axis. Endothelial dysfunction, which often develops in obesity and may lead to reduced nitric oxide availability, markedly augments the impact of leptin or MC4R activation on BP. For example, administration of the nitric oxide synthase inhibitor, L-NAME, markedly amplified the chronic hypertensive effects of leptin as well as of an MC4R agonist in rats [34, 35] .
In a recent study, Hilzendeger et al. [36] suggested that leptin may also interact with the brain RAAS to regulate SNS activity and BP. Obesity is also associated with reduced levels of factors believed to act in the CNS to reduce SNS and blunt the pressor effects of leptin and MC4R activation, including ghrelin and adiponectin [37] . However, the role of hypoghrelinemia, hypoadiponectemia, and increased angiotensin II levels in obesity, among other factors, in contributing to enhanced cardiovascular responses to leptin or MC4R activation has, to our knowledge, not been examined and remains unclear.
CONCLUSION
Obesity is a major cause of hypertension and cardiovascular diseases worldwide. Excess weight gain is associated with SNS activation, which contributes to renal sodium retention and impaired pressure natriuresis. Increased circulating leptin levels and activation of the brain melanocortin system, in particular MC4R, are key factors in linking obesity, increased RSNA, and elevated BP (Fig. 2) . Recent studies suggest that the leptin-MC4R axis exerts differential control of appetite and metabolic and cardiovascular functions. Unraveling the sitespecific actions of leptin receptor and MC4R activation and the contributions of the different intracellular signaling pathways activated by the leptin receptor in controlling appetite, metabolic functions, and SNS activity is critical for the development of better antiobesity drugs with minimal cardiovascular and renal side-effects. 
